🔗 Share this article World Health Organization Issues Alert Over Critical Shortage of Obesity Medications Under a tenth of patients who could benefit from GLP-1 drugs such as Wegovy have access to them, caution the World Health Organization as it releases its initial advice on the drugs. With over a billion people worldwide now obese, it is advocating for increased and just access to these injectable treatments. Based on estimates, more than two billion are projected to be living with obesity by 2030 without intervention. "Our latest guidelines affirms that obesity is a chronic disease that can be managed with thorough and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and distribution challenges are key barriers to broad availability to the treatments that can aid individuals in losing significant body mass, explains the organization. Weight-Loss Drug Supply Crisis Despite the present best projected outlook, the supply of such drugs might only reach about 100 million people – under 10% of eligible patients, according to the health organization. The guideline calls on countries and companies to widen availability, by measures including licensing agreements. Exclusive production rights on a key compound – the core component of the drug Wegovy – is due to expire in several nations in 2026. How Obesity Jabs Operate GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so users consume fewer calories. People commonly begin shedding pounds in the initial weeks of starting on the regular doses. Studies points to patients may regain a significant portion after a year of halting the treatment, when their typical food cravings come back. Being above a healthy weight elevates your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and certain malignancies. Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
Under a tenth of patients who could benefit from GLP-1 drugs such as Wegovy have access to them, caution the World Health Organization as it releases its initial advice on the drugs. With over a billion people worldwide now obese, it is advocating for increased and just access to these injectable treatments. Based on estimates, more than two billion are projected to be living with obesity by 2030 without intervention. "Our latest guidelines affirms that obesity is a chronic disease that can be managed with thorough and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and distribution challenges are key barriers to broad availability to the treatments that can aid individuals in losing significant body mass, explains the organization. Weight-Loss Drug Supply Crisis Despite the present best projected outlook, the supply of such drugs might only reach about 100 million people – under 10% of eligible patients, according to the health organization. The guideline calls on countries and companies to widen availability, by measures including licensing agreements. Exclusive production rights on a key compound – the core component of the drug Wegovy – is due to expire in several nations in 2026. How Obesity Jabs Operate GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so users consume fewer calories. People commonly begin shedding pounds in the initial weeks of starting on the regular doses. Studies points to patients may regain a significant portion after a year of halting the treatment, when their typical food cravings come back. Being above a healthy weight elevates your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and certain malignancies. Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.